MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services. The company also provides maternal-fetal care, including inpatient and office-based clinical care to expectant mothers and their unborn babies through maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians consisting of maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, its pediatric cardiology care services comprise inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, and pediatric surgeons, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. Additionally, it provides radiology and teleradiology services. As of December 31, 2017, the company's network consisted of approximately 4,075 affiliated physicians. MEDNAX, Inc. was founded in 1979 and is based in Sunrise, Florida.
Industry, Sector and Symbol
Industry Hospitals
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:MD
CUSIP58502B10
Phone954-384-0175
Debt
Debt-to-Equity Ratio0.63
Current Ratio1.74
Quick Ratio1.74
Price-To-Earnings
Trailing P/E Ratio14.28
Forward P/E Ratio11.41
P/E Growth1.15
Sales & Book Value
Annual Sales$3.46 billion
Price / Sales1.23
Cash Flow$4.2666 per share
Price / Cash10.54
Book Value$32.74 per share
Price / Book1.37
Profitability
EPS (Most Recent Fiscal Year)$3.15
Net Income$320.37 million
Net Margins9.34%
Return on Equity10.13%
Return on Assets5.31%
Miscellaneous
Employees7,675
Outstanding Shares94,380,000
MEDNAX (NYSE:MD) Frequently Asked Questions
What is MEDNAX's stock symbol?
MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."
How were MEDNAX's earnings last quarter?
MEDNAX Inc (NYSE:MD) issued its quarterly earnings results on Monday, April, 30th. The company reported $0.89 EPS for the quarter, topping analysts' consensus estimates of $0.82 by $0.07. The business earned $901.90 million during the quarter, compared to the consensus estimate of $903.75 million. MEDNAX had a net margin of 9.34% and a return on equity of 10.13%. The company's quarterly revenue was up 7.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.75 earnings per share. View MEDNAX's Earnings History.
When is MEDNAX's next earnings date?
What guidance has MEDNAX issued on next quarter's earnings?
MEDNAX issued an update on its second quarter earnings guidance on Monday, April, 30th. The company provided EPS guidance of $1.04-1.09 for the period, compared to the Thomson Reuters consensus estimate of $1.07.
What price target have analysts set for MD?
12 analysts have issued twelve-month price objectives for MEDNAX's stock. Their predictions range from $50.00 to $62.00. On average, they expect MEDNAX's stock price to reach $55.5833 in the next year. View Analyst Ratings for MEDNAX.
Who are some of MEDNAX's key competitors?
Some companies that are related to MEDNAX include Ramsay Health Care Limited Fully Paid Ord. Shrs (RHC), Encompass Health (EHC), Healthscope (HSO), Select Medical (SEM), Magellan Health (MGLN), Primary Health Care (PRY), Medical Facilities (DR), Capitol Health (CAJ), Animalcare Group (ANCR), SunLink Health Systems (SSY), Spine Injury Solutions (SPIN) and THC Biomed Intl (THC).
Who are MEDNAX's key executives?
MEDNAX's management team includes the folowing people:
- Dr. Roger J. Medel, Co-Founder, CEO & Director (Age 71)
- Mr. Joseph M. Calabro, Pres & COO (Age 57)
- Ms. Vivian Lopez-Blanco, CFO & Treasurer (Age 60)
- Mr. Dominic J. Andreano, Sr. VP, Gen. Counsel & Sec. (Age 49)
- Mr. David A. Clark, Pres of Mednax National Medical Group Division (Age 51)
Has MEDNAX been receiving favorable news coverage?
News articles about MD stock have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MEDNAX earned a daily sentiment score of 0.08 on Accern's scale. They also gave news headlines about the company an impact score of 47.97 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are MEDNAX's major shareholders?
MEDNAX's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.34%), Blue Harbour Group L.P. (4.77%), Pzena Investment Management LLC (2.41%), Earnest Partners LLC (2.22%), Dimensional Fund Advisors LP (2.18%) and Wedge Capital Management L L P NC (2.09%). Company insiders that own MEDNAX stock include Cesar L Alvarez, David A Clark, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Paul G Gabos, Robert Irwin Valliant and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.
Which institutional investors are selling MEDNAX stock?
MD stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Thompson Siegel & Walmsley LLC, Cooke & Bieler LP, Flinton Capital Management LLC, Toronto Dominion Bank, Hsbc Holdings PLC, Tyers Asset Management LLC and Tiverton Asset Management LLC. Company insiders that have sold MEDNAX company stock in the last year include Cesar L Alvarez, David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro and Vivian Lopez-Blanco. View Insider Buying and Selling for MEDNAX.
Which institutional investors are buying MEDNAX stock?
MD stock was purchased by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, MUFG Securities EMEA plc, BNP Paribas Arbitrage SA, Blue Harbour Group L.P., Dimensional Fund Advisors LP, Millennium Management LLC, Prudential Financial Inc. and FIL Ltd. Company insiders that have bought MEDNAX stock in the last two years include Manuel Kadre and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.
How do I buy shares of MEDNAX?
Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEDNAX's stock price today?
One share of MD stock can currently be purchased for approximately $44.97.
How big of a company is MEDNAX?
MEDNAX has a market capitalization of $4.26 billion and generates $3.46 billion in revenue each year. The company earns $320.37 million in net income (profit) each year or $3.15 on an earnings per share basis. MEDNAX employs 7,675 workers across the globe.
How can I contact MEDNAX?
MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]
MarketBeat Community Rating for MEDNAX (MD)
MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days.
